IV ITRACONAZOLE VS AMPHOTERICIN B IN BLASTOMYCOSIS OR HISTOPLASMOSIS

本研究的主要目的是评估IV伊曲康唑与标准治疗（两性霉素B）相比的安全性。 本研究还将评估IV诱导治疗结束时（7-14天）和PO巩固治疗后第2、12和24周的临床、微生物学和总体治疗应答。患者将随机接受初始治疗，IV伊曲康唑，每日两次，持续2天（负荷剂量），然后每日一次，持续5天，或IV阿替霉素B，持续7天。 扩展治疗后将进行伊曲康唑胶囊每日一次或每日两次巩固治疗，持续1年。在诱导治疗期间（7-14天），在1小时内静脉输注伊曲康唑。 IV两性霉素B在1-6小时内输注。巩固治疗同上。

The primary purpose of this study is to assess the safety of IV intraconazole compared to the standard of care (Amphotericin B). The study will also assess the clinical, microbiological, and overall response to therapy at the end of IV induction therapy (7-14 days) and after PO consolidation therapy at 2,12, and 24 weeks. Patients will be randomized to either an initial treatment with IV intraconazole twice daily for 2 days (loading dose) and then once daily for 5 additional days or amphotericin-B by IV for 7 days. Extended treatment will be followed by consolidation therapy with itraconazole capsules once daily or twice daily for up to 1 year. During induction therapy (7-14 days) IV intraconazole is infused over a 1-hour period. IV Amphotericin-B is infused over a 1-6 hour period. Consolidation therapy is the same as above.